NASDAQ:CYCCCyclacel Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.36 +0.19 (+3.68 %) (As of 05/25/2020 04:00 PM ET) Add Compare Share Today's Range$5.16Now: $5.36▼$5.6950-Day Range$0.37MA: $3.74▼$8.6452-Week Range$3.85Now: $5.36▼$20.40Volume1.89 million shsAverage Volume498,797 shsMarket Capitalization$26.04 millionP/E RatioN/ADividend YieldN/ABeta1.17 ProfileAnalyst RatingsAdvanced ChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor that is in all-oral Phase 1/2 combination study with sapacitabine for BRCA mutations. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias; and collaboration, licensing, and supply agreement with ManRos Therapeutics SA for the development and commercialization of oral seliciclib capsules for the treatment of cystic fibrosis. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Cyclacel Pharmaceuticals. Previous Next 2.4 Community Rank Outperform VotesCyclacel Pharmaceuticals has received 176 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCyclacel Pharmaceuticals has received 198 “underperform” votes. (Add your “underperform” vote.)Community SentimentCyclacel Pharmaceuticals has received 52.94% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cyclacel Pharmaceuticals and other stocks. Vote “Outperform” if you believe CYCC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CYCC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCyclacel Pharmaceuticals does not currently pay a dividend.Dividend GrowthCyclacel Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cyclacel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.09% of the stock of Cyclacel Pharmaceuticals is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Cyclacel Pharmaceuticals are expected to grow in the coming year, from ($2.54) to ($1.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cyclacel Pharmaceuticals is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cyclacel Pharmaceuticals is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCyclacel Pharmaceuticals has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.73 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CYCC Previous Symbol CUSIPN/A CIK1130166 Webwww.cyclacel.com Phone908-517-7330Debt Debt-to-Equity Ratio0.10 Current Ratio7.76 Quick Ratio7.76Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$150,000.00 Price / Sales173.63 Cash FlowN/A Price / Cash FlowN/A Book Value$13.60 per share Price / Book0.39Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-7,830,000.00 Net MarginsN/A Return on Equity-56.33% Return on Assets-44.89%Miscellaneous Employees14 Outstanding Shares4,859,000Market Cap$26.04 million Next Earnings Date8/11/2020 (Estimated) OptionableNot Optionable NASDAQ:CYCC Rates by TradingView Receive CYCC News and Ratings via Email Sign-up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. Cyclacel Pharmaceuticals (NASDAQ:CYCC) Frequently Asked Questions How has Cyclacel Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Cyclacel Pharmaceuticals' stock was trading at $0.5399 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CYCC stock has increased by 892.8% and is now trading at $5.36. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Cyclacel Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cyclacel Pharmaceuticals. When is Cyclacel Pharmaceuticals' next earnings date? Cyclacel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Cyclacel Pharmaceuticals. How were Cyclacel Pharmaceuticals' earnings last quarter? Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) announced its earnings results on Tuesday, May, 12th. The biotechnology company reported ($1.48) earnings per share for the quarter, topping the Zacks' consensus estimate of ($2.90) by $1.42. View Cyclacel Pharmaceuticals' earnings history. When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work? Cyclacel Pharmaceuticals shares reverse split before market open on Wednesday, April 15th 2020. The 1-20 reverse split was announced on Tuesday, April 14th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 14th 2020. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 5 shares after the split. Has Cyclacel Pharmaceuticals been receiving favorable news coverage? Press coverage about CYCC stock has been trending somewhat positive recently, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cyclacel Pharmaceuticals earned a coverage optimism score of 2.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutCyclacel Pharmaceuticals. Are investors shorting Cyclacel Pharmaceuticals? Cyclacel Pharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totaling 125,400 shares, an increase of 1,040.0% from the April 30th total of 11,000 shares. Based on an average daily trading volume, of 468,900 shares, the short-interest ratio is currently 0.3 days. Approximately 15.1% of the company's stock are short sold. View Cyclacel Pharmaceuticals' Current Options Chain. Who are some of Cyclacel Pharmaceuticals' key competitors? Some companies that are related to Cyclacel Pharmaceuticals include Eton Pharmaceuticals (ETON), Oncolytics Biotech (ONCY), CV Sciences (CVSI), Aptorum Group (APM), Catalyst Biosciences (CBIO), Bellerophon Therapeutics (BLPH), TFF Pharmaceuticals (TFFP), CannTrust (CTST), Genprex (GNPX), Sesen Bio (SESN), Clearside Biomedical (CLSD), Celsion (CLSN), Proteostasis Therapeutics (PTI), ContraFect (CFRX) and Milestone Pharmaceuticals (MIST). View all competitors. What other stocks do shareholders of Cyclacel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Novavax (NVAX), McEwen Mining (MUX), NVIDIA (NVDA), Exelixis (EXEL) and Boeing (BA). Who are Cyclacel Pharmaceuticals' key executives? Cyclacel Pharmaceuticals' management team includes the following people: Mr. Spiro George Rombotis, Pres, CEO & Exec. Director (Age 60)Mr. Paul McBarron, Exec. VP of Fin., CFO, COO, Sec. & Exec. Director (Age 58)Dr. Judy H. Chiao, VP of Clinical Devel. & Regulatory Affairs (Age 59)Ms. Gill Christie, Director of HR (Age 62)Dr. Robert Westwood Ph.D., Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel. (Age 75) What is Cyclacel Pharmaceuticals' stock symbol? Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC." How do I buy shares of Cyclacel Pharmaceuticals? Shares of CYCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cyclacel Pharmaceuticals' stock price today? One share of CYCC stock can currently be purchased for approximately $5.36. How big of a company is Cyclacel Pharmaceuticals? Cyclacel Pharmaceuticals has a market capitalization of $26.04 million and generates $150,000.00 in revenue each year. Cyclacel Pharmaceuticals employs 14 workers across the globe. What is Cyclacel Pharmaceuticals' official website? The official website for Cyclacel Pharmaceuticals is www.cyclacel.com. How can I contact Cyclacel Pharmaceuticals? Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company can be reached via phone at 908-517-7330 or via email at [email protected] This page was last updated on 5/26/2020 by MarketBeat.com Staff
